Answers are grounded in this paper and cite their sources.
Review summarizes IL-37's expression and mechanisms in IBD and colitis-associated colorectal cancer, suggesting clinical insights.
Inflammatory bowel disease (IBD) is an idiopathic inflammatory disorder of intestine and a high risk for colorectal cancer; however, its precise etiology and pathogenesis remain poorly understood. Interleukin (IL)-37, a member of IL-1 family, exerts anti-inflammatory effects in various inflammatory diseases and cancers, and is generated by several epithelial cells and immune cells. Mechanistically, IL-37 mediates its anti-inflammatory either by translocating into nucleus in complex with small mother against decapentaplegic homolog 3 or binding to extracellular interleukin-18 receptor and IL-1 receptor-related receptor 8 (IL-1R8), which is abundantly expressed in the gastrointestinal tract. Recently, accumulating evidence has demonstrated that IL-37 expression is upregulated and plays protective roles in IBD and colitis-associated cancer (CAC). This review summarizes the recent advances regarding the expression, biological functions, molecular mechanism, and therapeutic potential of IL-37 in IBD and CAC, aiming to provide novel insights into its underlying mechanism and clinical application.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: